Jane Street Group LLC Acquires 25,416 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO)

Jane Street Group LLC boosted its holdings in Sutro Biopharma, Inc. (NASDAQ:STRO) by 30.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 108,192 shares of the company’s stock after purchasing an additional 25,416 shares during the period. Jane Street Group LLC owned about 0.13% of Sutro Biopharma worth $374,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Gladius Capital Management LP acquired a new stake in shares of Sutro Biopharma during the 3rd quarter worth about $28,000. ProShare Advisors LLC lifted its stake in shares of Sutro Biopharma by 49.1% during the 2nd quarter. ProShare Advisors LLC now owns 16,316 shares of the company’s stock worth $48,000 after buying an additional 5,373 shares during the last quarter. Intech Investment Management LLC acquired a new stake in shares of Sutro Biopharma during the 3rd quarter worth about $91,000. The Manufacturers Life Insurance Company lifted its stake in shares of Sutro Biopharma by 27.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 32,943 shares of the company’s stock worth $97,000 after buying an additional 7,082 shares during the last quarter. Finally, SG Americas Securities LLC lifted its stake in shares of Sutro Biopharma by 134.6% during the 3rd quarter. SG Americas Securities LLC now owns 34,662 shares of the company’s stock worth $120,000 after buying an additional 19,890 shares during the last quarter. Institutional investors own 96.99% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on STRO shares. Wells Fargo & Company cut their target price on shares of Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating for the company in a research note on Wednesday, December 11th. Piper Sandler reiterated an “overweight” rating and issued a $11.00 price objective on shares of Sutro Biopharma in a research note on Friday, October 11th. HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of Sutro Biopharma in a research note on Monday, November 18th. JMP Securities reiterated a “market outperform” rating and issued a $17.00 price objective on shares of Sutro Biopharma in a research note on Wednesday, December 11th. Finally, Wedbush reiterated an “outperform” rating and issued a $8.00 price objective on shares of Sutro Biopharma in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, Sutro Biopharma currently has an average rating of “Moderate Buy” and an average price target of $11.13.

Sutro Biopharma Trading Down 3.5 %

Shares of NASDAQ:STRO opened at $1.95 on Thursday. The firm has a 50 day moving average of $2.66 and a 200-day moving average of $3.39. The stock has a market capitalization of $160.80 million, a PE ratio of -1.21 and a beta of 1.15. Sutro Biopharma, Inc. has a 12 month low of $1.70 and a 12 month high of $6.13.

Sutro Biopharma Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.